Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
The OHART Study
The purpose of this study is to investigate different oral and systemic problems including dental carries, periodontal disease, dry mouth, high cholesterol, diabetes, heart disease, and osteoporosis, observed in patients living with HIV on antiretroviral therapy.
LEADS
This research study is being done to learn about certain characteristics of the skin and how these characteristics are related to the severity of atopic dermatitis (AD) and the skins response to treatment. Subjects 18 and older diagnosed with AD and Non Ad subjects.Procedures include vital signs, pregnancy status (if applicable), and any updates regarding medical history and current medications or therapies. Collection of blood, skin swabs, skin tape strips, and/or skin biopsies
HPTN 102: LEN in Women (HIV Prevention Medication)
Phase 2
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
MVT-601A-006 MOXIE
The primary objective of this study is to characterize changes in bone mineral density (BMD) during continuous treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) for up to 48 months (4 years) in two cohorts: (1) premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and (2) premenopausal women with moderate to severe pain associated with endometriosis.
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)
Phase 3
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
